- home
- facet
- KM Biologics
KM Biologics
perspectives
countries
- 1.United States
- 2.China
- 3.Denmark
- 4.France
- 5.United Kingdom
- 6.Japan
- 7.Kenya
- 8.Mozambique
- 9.Nigeria
- 10.Philippines
- 11.Pakistan
- 12.Russian Federation
organizations
- 1.World Health Organization
- 2.Africa Centers for Disease Control and Prevention
- 3.Bavarian Nordic
- 4.European Union
- 5.Pasteur Institute
- 6.United Nations
- 7.US Centers for Disease Control and Prevention
- 8.Emergent BioSolutions
- 9.European Center for Disease Prevention and Control
- 10.European Commission
- 11.European Health Emergency Preparedness and Response Authority
- 12.Public Health Agency
persons
- 1.Dimie Ogoina
- 2.Jean Kaseya
- 3.Federico Jofré
- 4.Hans Kluge
- 5.Kocha Olarn
- 6.Magnus Gisslen
- 7.Mauricio Torres
- 8.Maya Davis
- 9.Paul Chaplin
- 10.Stuart Blume
- 11.Tedros Adhanom Ghebreyesus
- 12.Ayona Munyakazia
technicals
- 1.Clade I mpox
- 2.Covid-19 Pandemic
- 3.Imvanex
- 4.Jynneos
- 5.LC16
- 6.mpox
- 7.ACAM2000
- 8.Hera
- 9.Imvamune
- 10.OrthopoxVac
- 11.MVA-BN